JP2023548443A5 - - Google Patents
Info
- Publication number
- JP2023548443A5 JP2023548443A5 JP2023551651A JP2023551651A JP2023548443A5 JP 2023548443 A5 JP2023548443 A5 JP 2023548443A5 JP 2023551651 A JP2023551651 A JP 2023551651A JP 2023551651 A JP2023551651 A JP 2023551651A JP 2023548443 A5 JP2023548443 A5 JP 2023548443A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063107942P | 2020-10-30 | 2020-10-30 | |
| US63/107,942 | 2020-10-30 | ||
| US202063123329P | 2020-12-09 | 2020-12-09 | |
| US202063123327P | 2020-12-09 | 2020-12-09 | |
| US63/123,327 | 2020-12-09 | ||
| US63/123,329 | 2020-12-09 | ||
| US202163141268P | 2021-01-25 | 2021-01-25 | |
| US63/141,268 | 2021-01-25 | ||
| US202163187699P | 2021-05-12 | 2021-05-12 | |
| US202163187719P | 2021-05-12 | 2021-05-12 | |
| US202163187690P | 2021-05-12 | 2021-05-12 | |
| US63/187,719 | 2021-05-12 | ||
| US63/187,690 | 2021-05-12 | ||
| US63/187,699 | 2021-05-12 | ||
| US202163189843P | 2021-05-18 | 2021-05-18 | |
| US63/189,843 | 2021-05-18 | ||
| PCT/US2021/057384 WO2022094299A2 (en) | 2020-10-30 | 2021-10-29 | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548443A JP2023548443A (ja) | 2023-11-16 |
| JP2023548443A5 true JP2023548443A5 (https=) | 2024-11-07 |
| JPWO2022094299A5 JPWO2022094299A5 (https=) | 2024-11-07 |
Family
ID=81384468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551651A Pending JP2023548443A (ja) | 2020-10-30 | 2021-10-29 | Ｃｄ２８およびｐｄ－ｌ１を標的とする多特異性抗体ならびにその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230406937A1 (https=) |
| EP (1) | EP4237013A4 (https=) |
| JP (1) | JP2023548443A (https=) |
| KR (1) | KR20230136913A (https=) |
| AU (1) | AU2021369835A1 (https=) |
| CA (1) | CA3196726A1 (https=) |
| MX (1) | MX2023005081A (https=) |
| WO (1) | WO2022094299A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| JP2024518539A (ja) | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| EP4259177A4 (en) * | 2020-12-08 | 2024-11-06 | Janux Therapeutics, Inc. | Peptide compositions and methods for anti-cd3 binding domains |
| JP2024511319A (ja) | 2021-03-09 | 2024-03-13 | ゼンコア インコーポレイテッド | Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体 |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CA3267921A1 (en) | 2022-10-06 | 2024-04-11 | Bicara Therapeutics Inc. | MULTISPECIFIC PROTEINS AND ASSOCIATED PROCESSES |
| WO2024102723A2 (en) * | 2022-11-10 | 2024-05-16 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| EP4615879A2 (en) * | 2022-11-11 | 2025-09-17 | Janux Therapeutics, Inc. | Compositions and uses of tumor activated antibodies targeting egfr and effector cell antigens |
| CN121532427A (zh) * | 2023-05-18 | 2026-02-13 | 首尔大学校产学协力团 | 抗cd40l/抗cd28双特异性抗体及其用途 |
| WO2025026356A1 (zh) * | 2023-07-31 | 2025-02-06 | 百奥泰生物制药股份有限公司 | 靶向肿瘤相关抗原与cd28的双特异性抗体及其应用 |
| WO2025090973A2 (en) * | 2023-10-27 | 2025-05-01 | Xencor, Inc. | Anti-trop2 x anti-pdl1 x anti-cd28 antibodies |
| TW202528349A (zh) * | 2023-11-03 | 2025-07-16 | 美商詹努克斯治療有限公司 | 用於靶向psma及cd28之抗體及其用途 |
| TW202535942A (zh) * | 2023-11-03 | 2025-09-16 | 美商詹努克斯治療有限公司 | 用於靶向cd28之抗體及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018520650A (ja) * | 2015-05-21 | 2018-08-02 | アリゲーター・バイオサイエンス・アーベー | 新規のポリペプチド |
| EP3307778A1 (en) * | 2015-06-12 | 2018-04-18 | Bristol-Myers Squibb Company | Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways |
| US20190233534A1 (en) * | 2016-07-14 | 2019-08-01 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| JP2019529499A (ja) * | 2016-09-30 | 2019-10-17 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 組織指向性発現を用いた抗体ベースの遺伝子治療 |
| EP3645050A4 (en) * | 2017-06-25 | 2021-08-11 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| EA202090003A1 (ru) * | 2017-07-06 | 2020-06-18 | Мерус Н.В. | Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка |
| US20220017617A1 (en) * | 2018-07-09 | 2022-01-20 | Shanghai Epimab Biotherapeutics Co., Ltd. | Efficiently expressed egfr and pd-l1 bispecific binding proteins |
| JP2022513495A (ja) * | 2018-12-21 | 2022-02-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 腫瘍標的化スーパーアゴニストｃｄ２８抗原結合分子 |
| TWI861039B (zh) * | 2018-12-21 | 2024-11-11 | 瑞士商赫孚孟拉羅股份公司 | 靶向腫瘤之促效cd28抗原結合分子 |
| WO2020198009A1 (en) * | 2019-03-22 | 2020-10-01 | Regeneron Pharmaceuticals, Inc. | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
-
2021
- 2021-10-29 WO PCT/US2021/057384 patent/WO2022094299A2/en not_active Ceased
- 2021-10-29 CA CA3196726A patent/CA3196726A1/en active Pending
- 2021-10-29 US US18/249,886 patent/US20230406937A1/en active Pending
- 2021-10-29 JP JP2023551651A patent/JP2023548443A/ja active Pending
- 2021-10-29 KR KR1020237017803A patent/KR20230136913A/ko active Pending
- 2021-10-29 MX MX2023005081A patent/MX2023005081A/es unknown
- 2021-10-29 EP EP21887650.6A patent/EP4237013A4/en active Pending
- 2021-10-29 AU AU2021369835A patent/AU2021369835A1/en active Pending